Amgen – Denosumab Studied for Prosthesis-Associated Osteolysis – Client Well being Information
THURSDAY, Jan. 21, 2021 (HealthDay Information) — For sufferers with symptomatic, radiographically confirmed osteolysis present process revision complete hip arthroplasty surgical procedure, a single dose of denosumab leads to a discount in osteoclast numbers, in keeping with a research revealed on-line Jan. 11 in The Lancet Rheumatology.
Mohit M. Mahatma, from the College of Sheffield in the UK, and colleagues performed a part 2 randomized, proof-of-concept superiority trial involving sufferers aged 30 years or older and scheduled for revision complete hip arthroplasty surgical procedure for symptomatic, radiographically confirmed osteolysis. Members had been randomly assigned to both subcutaneous denosumab or placebo. The between-group distinction in osteoclast quantity per millimeter of bone floor of biopsies taken from the osteolytic membrane-bone interface at surgical procedure eight weeks later was assessed as the first consequence.
Ten sufferers within the denosumab group and 12 within the placebo group had been assessed for the first consequence. The researchers discovered that in contrast with the placebo group, within the denosumab group, there have been 83 % fewer osteoclasts on the osteolysis membrane-bone interface (median, 0.05 versus 0.30 per mm). There have been no deaths or treatment-related severe opposed occasions reported.
“The outcomes of this proof-of-concept medical trial point out that denosumab is efficient at decreasing bone resorption exercise inside osteolytic lesion tissue and is properly tolerated throughout the limitations of the one dose used right here,” the authors write.
The research was funded by Amgen. Amgen offered denosumab and placebo freed from cost.
Summary/Full Textual content (subscription or cost may be required)
Editorial (subscription or cost may be required)